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2.46, 91.11% reduction). There were no significant im-
pacts on hospital utilization related to stroke (
 

 
0.03 per
100 patients), valve replacement (0.48) and fatal MI (0.13).
CONCLUSION: In this study, amlodipine is found to be
an effective agent in reducing hospital utilization related to
CVD, especially CHF, PTCA, CABG, stent, and angina, in
patients with clinical coronary artery disease relative to the
placebo. Further analysis will examine whether amlodipine
can reduce hospital care costs associated with CVD.
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Discontinuation of drug use constitutes a major barrier to
adequate control of high blood pressure. Although various
factors may be associated with discontinuation of treat-
ment, so far, very few causal associations have been studied.
OBJECTIVES: To examine the effect of an array of poten-
tial predisposing, enabling and reinforcing factors on dis-
continuation of initial antihypertensive medication.
METHODS: We conducted a prospective cohort study
through a network of 173 pharmacies across Canada who
identified individuals starting a new antihypertensive medi-
cation as a monotherapy. We excluded pregnant women,
individuals who were taking other antihypertensive medi-
cations at the same time, and those who took medications
for chronic heart failure, or angina. We interviewed sub-
jects by telephone four times over a 36 month period. We
analyzed data using a Cox’s proportional hazard model.
RESULTS: Out of 682 eligible subjects, 43% had discon-
tinued their initial medication at the end of the observation
period. Individuals more likely to discontinue their initial
medication were those who perceived side effects with the
initial medication (Adjusted Hazard Ratio (AHR)  1.91;
95% Confidence interval (CI)  1.47–2.48) and those who
believed the antihypertensive medication had no effect
(AHR  1.33; 95% CI  1.03–1.72). Insurance coverage
for antihypertensive medication had a protective effect
(AHR  0.74; 95% CI  0.55–0.99).
CONCLUSIONS: Persistence with newly prescribed medi-
cations could be improved by selecting antihypertensive
medications with fewer side effects, by changing misleading
perceptions of patients about their treatment, and by re-
moving economical barriers.
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OBJECTIVE: The economic burden of dementia combined
with financial crisis in public health systems makes study-
ing costs of dementia very important. In Germany only one
“bottom-up”-study (150 patient records) of office based
physicians demonstrated the burden of dementia disease.
Our study is the first one in Germany using social health in-
surance data to demonstrate the costs of dementia for the
social health insurance.
METHOD: Direct costs incurred in the outpatient sector
for diagnosis and treatment of dementia were calculated by
means of analysis of health insurance data from the statu-
tory health insurance fund (AOK) of the region Dresden/
Riesa. At a defined date (1st July 1993) a random sample of
7490 insured persons were selected from the AOK master
file. The following data was covered: personal data, pre-
scription sheets, claim forms with diagnosis, diagnostic and
therapeutic procedures. Information about hospital treat-
ment was available from 1st and 2nd quarter of 1994. Plain-
text diagnosis was transferred into ICD 10 code. Demented
patients were identified by ICD items F00 to F09 and I60
to I69. A control group of non-demented patients identical
to the dementia group in terms of age and sex was selected
from the AOK sample using the matched pair method (two
controls for each case).
RESULTS: 327 of 7490 insured persons were diagnosed as
demented (one-year prevalence: 4.4%). Diagnostic proce-
dures and non-pharmacological care interventions were or-
dered significantly more often in cases than in controls.
79.2% cases vs. 44.2% controls were prescribed at least one
of the drugs associated with dementia. Office based phy-
sicians are more often visited by demented than by non-
demented patients (23 vs. 90 visits per year). Hospitaliza-
tion rate in cases was higher than in controls (11,0 vs.
5,1%). This data allowed calculation of the total direct
costs covered by social health insurance in one year for a de-
mented patient: EUR 4080,64 (diagnostics EUR 1128,52;
medication EUR 1906,94; non-pharmacological care inter-
vention EUR 107,18; hospital EUR 977,13). Compared
with controls the following attributed costs per case per
year were found: Total EUR 823,80 (diagnostics EUR
247,22; medication EUR 387,65; non-pharmacological care
interventions EUR 93,30; hospital EUR104,64).
CONCLUSION: The data indicated, that demented pa-
tients are not treated properly. Recommendations for ratio-
nal treatment of dementia should be implemented in the
outpatient setting.
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